Panmure Gordon reaffirmed their buy rating on shares of Scancell Holdings Plc (LON:SCLP) in a research report sent to investors on Monday morning. They currently have a GBX 68 ($0.84) price objective on the stock.
Scancell Holdings Plc (LON:SCLP) opened at 16.25 on Monday. The company has a 50 day moving average price of GBX 16.73 and a 200-day moving average price of GBX 17.13. The firm’s market capitalization is GBX 42.50 million. Scancell Holdings Plc has a one year low of GBX 12.00 and a one year high of GBX 25.90.
Scancell Holdings Plc Company Profile
Scancell Holdings plc develops immunotherapies for the treatment of cancer. The Company develops immunotherapies based on its ImmunoBody and Moditope technology platforms. Its ImmunoBody, SCIB1, is being developed for treatment of melanoma and is being evaluated in Phase I/II clinical trial. Its clinical trials demonstrated that SCIB1, when used as monotherapy, has an effect on tumor load, produces a melanoma-specific immune response and survival trend without serious side effects.
Receive News & Ratings for Scancell Holdings Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scancell Holdings Plc and related companies with MarketBeat.com's FREE daily email newsletter.